Cell surface her2/neu oncoprotein expression in breast ductal carcinoma

Breast cancer is a malignant tumor mostly disclosed in women. It has heterogeneous biological behavior - so that the knowledge of tumor markers is very important to determine its prognosis and therapy. Up to now, the determination of prognosis and treatment of choice is still based on clinical and morphologic finding although recent studies pointed out that there was tight relationship between carcinoma growth and molecular abnormalities including normal cell gene consisting of proto-oncogene, tumor suppressor gene, programmed cell death and DNA repair gene. Therefore, the description of molecular changes is required - in determining the prognosis and therapy of breast cancer. Molecular pathologic approach may offer a prospective promise even though the genetic mechanism of molecular carcinogenesis of breast cancer is still unclear. In this study, immunopathologic investigation was carried out by using immunohistochemical method, with antibody monoclonal against protein HER2/neu. Based on multivariate test of Wilks' Lambda method, protein expression of HER2/neu was concomitantly different in various tumor diameters of breast cancer (p = 0.000 < a = 0.05). With method of Wilks' Lambda method, protein expression HER2/neu was simultaneously different in various carcinoma cell differentiation of breast cancer (p = 0,000 < a = 0.05) and with Wilks' Lambda method, protein expression HER2/neu, was concomitantly different in various progressiveness of ductal carcinoma growth (p= 0,000 < a = 0.05). Also with Wilks' Lambda method, protein expression HER2/neu was concomitantly different in various grade of ductal carcinoma (p = 0.000 < a = 0.05). It showed that cancer of the breast occurred in genetic lesion